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ABSTRACT  19 
 20 
Phthalates, known as reproductive toxicants and endocrine disruptors, are widely 21 
used as plasticizers in polyvinyl chloride products. The present study was 22 
conducted for risk identification of dermal exposure to phthalates. When dibutyl 23 
phthalate was applied to the skin of hairless rats and humans, only monobutyl 24 
phthalate appeared through the skin, and the permeability of the skin was higher 25 
than that after the application of the monoester directly. The inhibition of skin 26 
esterases made the skin impermeable to the metabolite following dermal 27 
exposure to dibutyl ester, whereas removal of the stratum corneum from the skin 28 
did not change the skin permeation behavior. Similar phenomena were observed 29 
for benzyl butyl phthalate. The skin permeability of monobenzyl phthalate was 30 
higher than that of monobutyl phthalate in humans, although the reverse was 31 
observed in rats. Species difference in skin permeation profile corresponded to 32 
the esterase activity of the skin homogenate. Di(2-ethylhexyl) phthalate, which 33 
was not metabolized by esterases in the skin, was not transported across the 34 
skin. These results suggest that highly lipophilic phthalates may be transported 35 
easily across the stratum corneum lipids. The water-rich viable layer may become 36 
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permeable to these phthalates by their metabolism into monoesters, which are 37 
relatively hydrophilic. Skin metabolism is essential to the percutaneous 38 
absorption of phthalates. Because esterase activity has large inter-individual 39 
differences, further study will be needed for individual risk identification of 40 
dermal exposure to phthalates. 41 
 42 
Abbreviations: 43 
DBP: dibutyl phthalate 44 
BnBP: benzylbutyl phthalate 45 
DEHP: di(2-ethylhexyl) phthalate 46 
BP: monobutyl phthalate 47 
BnP: monobenzyl phthalate 48 
EHP: mono(2-ethylhexyl) phthalate 49 
PA: phthalic acid 50 
DFP: diisopropyl fluorophosphates 51 
HPLC: high-performance liquid chromatography 52 
PBS: phosphate-buffered saline 53 
DMSO: dimethyl sulfoxide 54 
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P: permeability coefficient 55 
V: formation rate of metabolites 56 
C: initial concentration 57 
Km: Michaelis constant 58 
Vmax: maximum metabolism rate 59 
  60 
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Introduction 61 
 62 
 Phthalates are used as plasticizers and solvents in the manufacturing of 63 
polyvinyl chloride-containing medical, building, and toy products (Graham, 1973). 64 
As these chemicals are non-covalently incorporated into plastics, they can leach 65 
out into the environment (Kamarei et al., 2011). We are daily exposed to 66 
phthalates owing to their broad use and large production (Blount et al., 2000). 67 
Several phthalates are suspected to be endocrine disruptors and reproductive 68 
toxicants; thus, their exposure to humans is a public health concern (Heudorf et 69 
al., 2007). In Japan, the Ministry of Health, Labor, and Welfare prohibits the use 70 
of phthalates in food packages and toys for babies, and limits their concentrations 71 
in indoor environment. However, scant attention has been paid to percutaneous 72 
absorption compared to ingestion and inhalation as entry routes of phthalates into 73 
the body (Hopf et al., 2014). 74 
 The skin is the largest organ interfacing directly with the environment, 75 
and it acts as a protective barrier against exogenous substances such as 76 
pathogens and chemicals (Proksch et al., 2008). Mammalian skin is composed 77 
of two primary layers, the epidermis and subjacent dermis. Stratum corneum, the 78 
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outermost layer of the epidermis, is a stratified squamous epithelium, which 79 
comprises enucleated keratinocytes, i.e. corneocytes, and intercellular lipid 80 
lamellae linked to the cornified envelope of the cells (Haftek et al., 2011). The 81 
structures surrounding the corneocytes contribute greatly to the skin’s barrier 82 
function and effectively prevent the permeation of numerous molecules across 83 
the barrier (Taylor et al., 1984). Conversely, one might say that compounds 84 
having adequate lipophilicity and small molecular weight can permeate through 85 
the stratum corneum. It is well known that the molecular weight of chemicals must 86 
be under 500 to allow skin absorption (Bos and Meinardi, 2000). The optimal 87 
lipophilicity of permeants across the stratum corneum was specified around 2.5, 88 
which is the logarithm of n-octanol/water partition coefficient (log P) (Yano et al., 89 
1986) and 10 cal1/2/cm1/2, which is the solubility parameter (Liron and Cohen, 90 
1984).  91 
 After penetrating via the stratum corneum, the molecules meet the viable 92 
epidermis comprising stratum granulosum, stratum spinosum, and stratum 93 
basale (Haftek et al., 2011). Since highly lipophilic compounds cannot distribute 94 
to the water-rich viable epidermis, they remain in the stratum corneum. These 95 
compounds hardly reach the blood vessels present in the dermis, and hence the 96 
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systemic blood circulation. However, the viable epidermis layer is the most 97 
metabolically active region in the skin (Laerum, 1969) and contains many of the 98 
same enzymes present in the liver (Kao and Carver, 1990). Therefore, any 99 
permeants via the stratum corneum are subjected to the metabolic functions of 100 
the living layer. Lack of metabolism would allow only the unchanged compounds 101 
to pass into the systemic circulation. Almost all biotransformation processes may 102 
produce inactive or less active metabolites, resulting in another barrier function 103 
of the skin against exogenous substances. There are reverse cases where the 104 
skin enzymes convert inactive chemicals into pharmacological and toxicological 105 
active agents (Zhang et al., 2009). If highly lipophilic compounds remaining in the 106 
stratum corneum are transformed to metabolites that are hydrophilic and capable 107 
to diffuse in the viable epidermis, the compounds will be absorbed into the body 108 
as those metabolites. Furthermore, if the metabolites are pharmacologically or 109 
toxicologically active, unexpected events can occur depending on the 110 
physicochemical properties of the parent compounds. 111 
 Phthalates are esters of phthalic acid (PA) and alcohols ranging from 112 
methanol to tridecyl alcohol, having either a straight chain or several branching. 113 
Their molecular weight ranges from 194.18 to 530.82, and lipophilicity remarkably 114 
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increases with increase in the length of alcohol chain. We reported that the 115 
esterase activity in rodent and human skin was high enough to affect the skin 116 
permeation profiles of ethyl nicotinate (Rittirod et al., 1990; Sugibayashi et al., 117 
1996). Several hydrolyzed metabolites of phthlates, i.e. monophthalates, are 118 
known as reproductive toxicants (Bonilla and del Mazo, 2010; Muczynski et al., 119 
2012). It is important to know the skin permeation profiles of phthalates, and the 120 
influence of metabolism on these profiles from the viewpoint of safety. 121 
 The present study was conducted for risk identification of dermal 122 
exposure to phthalates. In vitro skin permeation profiles of three popular 123 
plasticizers were evaluated in hairless rat skin. Skin permeability and skin 124 
concentration of phthalates and their monoester metabolites were measured. The 125 
esterase activities in skin homogenate were determined, and the metabolic 126 
parameters were compared among phthalates. In addition, the permeation 127 
characteristics and enzymatic activity of human skin were assessed and 128 
compared with those of rat skin.  129 
  130 
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Materials and methods 131 
 132 
Materials 133 
Dibutyl phthalate (DBP), benzyl butyl phthalate (BnBP), di(2-ethylhexyl) 134 
phthalate (DEHP), monobutyl phthalate (BP), monobenzyl phthalate (BnP), 135 
mono(2-ethylhexyl) phthalate (EHP), PA, and diisopropyl fluorophosphates (DFP) 136 
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The 137 
physicochemical properties of phthalates used as permeants are listed in Table 138 
1. Other reagents and solvents of special grade or HPLC grade were 139 
commercially obtained and used without further purification.  140 
 141 
Table 1 142 
 143 
  144 
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Preparation of skin membranes  145 
 146 
Male hairless rats (WBN/Ila-Ht, 8–10 weeks of age, with body weight of 147 
220–260 g) were obtained from the Life Science Research Center, Josai 148 
University (Sakado, Saitama, Japan) or Ishikawa Experimental Animal 149 
Laboratories (Fukaya, Saitama). The abdominal skin was freshly excised under 150 
anesthesia by an intraperitoneal injection (i.p.) injection of pentobarbital (50 151 
mg/kg) immediately before permeation and metabolism experiments. The 152 
stripped skin was prepared by stripping the stratum corneum 20 times with a 153 
cellophane tape (CellotapeTM, No. 405, Nichiban Co. Ltd., Tokyo, Japan) (Flynn 154 
et al., 1981). All animal experiments were approved by the Institutional Animal 155 
Care and Use Committee of Josai University.  156 
 Four pieces of frozen abdominal skin of two female Caucasians (51 157 
and 55 years old; mean skin thickness of 500 and 550 μm, respectively) 158 
were purchased from Biopredic International (Saint Grégoire, France) through 159 
KAC (Kyoto, Japan). The skins were stored at -50°C and thawed at 32°C just 160 
before the experiments. The stripped skins were made by the same method used 161 
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for rat skin. All human skin studies were carried out in accordance with the 162 
guidelines for the ethical use of human-organs and tissues in KAC. 163 
 164 
Skin permeation experiments 165 
 166 
Excess subcutaneous fat was trimmed off from the full-thickness or 167 
stripped skin of rat or humans. Each skin membrane was mounted on a side-by-168 
side diffusion cell (effective diffusion area of 0.95 cm2) in which the donor (stratum 169 
corneum side) and receiver (dermis side) chambers were prewarmed to 32°C. 170 
The skin was hydrated by filling both chambers with 2.5 mL of pH 7.4 phosphate 171 
buffered saline (PBS) for 30 min (rat) and 12 h (human) prior to starting BP and 172 
DBP permeation experiments. When the permeant was BnP, BnBP, EHP, or 173 
DEHP, 10% dimethyl sulfoxide (DMSO-PBS) was used instead of PBS. Under 174 
experimental conditions where hydrolysis is inhibited by esterase in the skin, DFP, 175 
a serine protease inhibitor, was added to the solutions at a concentration of 2.7 176 
mM (Sugibayashi et al., 1996). After hydration, the solutions in the donor and 177 
receiver chambers were replaced with the same volume of phthalate solution and 178 
fresh PBS or 10% DMSO-PBS. BP and DBP were applied to the skin in 4.0 and 179 
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0.718 mM PBS, respectively. The donor concentration in 10% DMSO-PBS was 180 
4.0, 1.4, 0.4, and 0.256 mM for BnP, EHP, BnBP, and DEHP, respectively. 181 
Receiver solutions containing 0.54 mM DFP were used for the complete inhibition 182 
of esterase activity in the skin. Donor and receiver solutions were stirred by a 183 
magnetic stirrer with a stirring bar and maintained at 32°C throughout the 184 
experiments. The receiver solution was periodically sampled, and the same 185 
volume of fresh PBS or 10% DMSO-PBS was added to the receiver chamber to 186 
keep the volume constant. The samples were stored at 4°C until determination of 187 
permeant concentration. The experiments were continued for 6-48 h 188 
until permeation reached the steady state. 189 
 190 
Determination of skin concentrations 191 
 192 
After permeation experiments, the skin was demounted from the diffusion 193 
cell, and washed three times with 1 mL of fresh receiver solution to completely 194 
remove phthalates remaining on the skin surface. The effective permeation area 195 
of the skin was minced with scissors and an appropriate volume of fresh receiver 196 
solution was added to make 4 w/v% skin homogenate. Homogenization was 197 
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performed using a homogenizer (Polytron PT-MR 3000, Kinematica, Switzerland) 198 
at 10,000 g for 3 min at 4°C. The homogenate was centrifuged at 15,000 g for 5 199 
min at 4°C, and the resulting supernatant was stored at 4°C until determination 200 
of phthalate concentration. 201 
 202 
Metabolism experiments in skin homogenates 203 
 204 
Skin homogenates (10% w/v) were made with freshly excised rat skin or 205 
thawed human skin and PBS as described above. The homogenates were 206 
centrifuged at 9,000 g for 5 min at 4°C. The supernatants and various 207 
concentrations of phthalate solutions (BP and DBP in PBS, and BnP, BnBP, EHP, 208 
and DEHP in 10% DMSO-PBS) were preincubated for 30 min at 37°C and mixed, 209 
such that the final concentration of each phthalate was 5–100 μM and that of the 210 
skin homogenate was 0.25 (rat) or 0.75% (human), respectively. The solution was 211 
kept at 37°C and periodically sampled for 120 min. The sample was stored at 4°C 212 
until determination of phthalate concentration.  213 
 214 
Analytical methods 215 
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 216 
The samples were vortex-mixed with the same volume of acetonitrile and 217 
centrifuged at 18,800 g and 4°C for 5 min. Phthalates in the supernatant (20 μL) 218 
were quantified by an HPLC system (Shimadzu Co., Kyoto), which was equipped 219 
with CBM-20A system controller, LC-20AD pump, SIL-20AC auto injector, SPD-220 
20AC UV/Visible detector, CTO-20AC column oven, and LC solution analysis 221 
software. Cadenza CD-C18 column (4.6 x 75 mm, Imtakt Corporation, Kyoto) 222 
packed with C18 silica reversed-phase particles of 3 μm and kept at 40°C was 223 
used in this study. The flow rates of mobile phases were set to 1 mL/min. An 224 
isocratic mobile phase comprising 65 % mobile phase A (aqueous 0.5 % 225 
phosphoric acid) and 35 % mobile phase B (acetonitrile) was used for the 226 
determination of BP and DBP, which resulted in retention times of 1.6 and 6.3 min, 227 
respectively. Simultaneous analysis of BP, BnP, and BnBP was carried out with a 228 
linear gradient elution system as follows: initial mobile phase, comprising 32.5% 229 
A and 67.5% B, maintained for 9 min, changed linearly to 20% A and 80% B in 4 230 
min, held for an additional 7 min, and returned to the original composition in 3 231 
min. This resulted in retention times of 9, 11, and 18 min. The elution system for 232 
EHP and DEHP included holding 30% A and 70% B for 4 min, a linear gradient 233 
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to 100% B in 4 min and keeping for another 4 min, and returning to the original 234 
composition in 3 min. Their retention times were 3 and 12 min, respectively. The 235 
detection wavelength for DBP and BP was 254 nm and that for other phthalates 236 
was 280 nm. The lower limit of quantitation was 9.88, 50.0, 25.6, 10.0, 9.62, and 237 
89.8 pmol for DBP, BnBP, DEHP, BP, BnP, and EHP, respectively. The extraction 238 
ratio of phthalates was almost 1.0.  239 
 The protein content in skin homogenates used for metabolism 240 
experiments of phthalates was determined by Lowry’s method (Lowry et al., 241 
1951). 242 
 243 
Data analysis 244 
 245 
The skin permeability of phthalates was assessed using the permeability 246 
coefficient P, which is a parameter calculated as the steady-state permeation rate 247 
(flux) divided by the permeant concentration exposed to skin surface. During skin 248 
permeation, when the parent phthalates were completely converted into certain 249 
metabolites by skin enzymes, the apparent P, which is the steady-state flux of 250 
metabolite divided by the concentration of parent phthalate applied to the skin, 251 
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was used as an alternative to true P. The metabolism of phthalates was quantified 252 
by the formation rate (V) of metabolites at various initial concentrations (C) of 253 
parent phthalate in the skin homogenate solution. The V-C data were fitted to 254 
Hanes-Woolf equation [C/V=C/Vmax+Km/Vmax] using linear regression to calculate 255 
metabolic parameters such as Michaelis constant (Km) and the maximum 256 
metabolism rate (Vmax). 257 
 258 
Results 259 
 260 
Skin permeation and concentration of DBP 261 
 262 
The skin permeation profiles and skin concentrations, respectively, of 263 
phthalates after applying DBP to the excised rat abdominal skin are shown in 264 
Figure 1A and B. Although DBP was applied to the skin surface, only BP, an active 265 
monoester metabolite of DBP, permeated through the skin. The apparent 266 
permeability coefficient, which is the steady-state flux of BP divided by the 267 
concentration of DBP applied to skin, is listed in Table 2. BP but not DBP existed 268 
inside the skin after the permeation experiments. When the skin was treated with 269 
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DFP, a serine-esterase inhibitor, DBP and BP did not transport through the skin 270 
and only DBP was detected in the skin.  271 
The corresponding data for the stratum corneum-stripped skin 272 
(stripped skin) are shown in Fig. 1C and D and listed in Table 2. Despite the 273 
absence of stratum corneum, which is the main barrier of skin permeation, the 274 
permeation characteristics were similar to those for full-thickness skin. Both 275 
permeation and existence of BP were observed in DFP-untreated skin. No 276 
permeation was found in DFP-treated skin, but DBP was detected in the skin. 277 
 278 
Fig. 1 and Table 2 279 
 280 
Skin permeation and concentration of phthalate diesters 281 
 282 
Skin permeation and concentration of phthalates other than DBP were 283 
also assessed. The skin permeation properties of BnBP, an alkyl aryl ester of PA, 284 
after application to full-thickness skin is shown in Figure 2A. BnP and BP, the 285 
monoester metabolites of BnBP, were transported across the skin, whereas BnBP 286 
was not. The apparent permeability coefficient of BP was 6.5-fold higher than that 287 
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of BnP (Table 2). The applied diester and two metabolites were detected in the 288 
skin after permeation experiment, although the concentration of BnBP was lower 289 
than that of BP (Fig. 2B). Inhibition of skin esterase made two metabolites 290 
impermeable across the skin, resulting in the presence of BnBP alone in the skin. 291 
Stripped skin had permeation characteristics similar to full-thickness skin (Table 292 
2). 293 
 294 
Fig. 2 295 
 296 
Neither DEHP nor its monoester metabolite, EHP, was transported 297 
through the skin when DEHP was applied to the full-thickness skin. The skin 298 
concentrations of two phthalates were under the detection limits 48 h after 299 
applying DEHP. Tape stripping and esterase inhibition did not affect the skin 300 
permeation properties of DEHP.  301 
 302 
Skin permeation of phthalate monoesters 303 
 304 
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The permeation properties of phthalate monoesters after their application 305 
to the skin were evaluated and compared with those after the application of 306 
corresponding diesters (Table 2). As mentioned above, little difference was 307 
observed in the apparent permeability coefficient of phthalate monoesters (BP 308 
and BnP), which were the products of metabolism during the skin transport of 309 
phthalate diesters (DBP and BnBP), between full-thickness and stripped skin. In 310 
contrast, on removal of the stratum corneum, the permeability coefficient of all 311 
tested monoesters (BP, BnP, and EHP) after application to the skin increased 312 
remarkably.  313 
 314 
Species differences in skin permeation and concentration of phthalate diesters 315 
 316 
Skin permeation experiments of phthalate diesters were carried out using 317 
excised human skin, and the results were compared with those of rat skin. The 318 
results of BnBP permeation experiment using full-thickness human skin is shown 319 
in Figure 2C and D. No BnBP permeation was observed through human skin, 320 
which is similar to the finding observed in rat skin. However, the permeability of 321 
BnP was higher than that of BP contrary to that in rat skin. In agreement with the 322 
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permeability data, a higher concentration of BnP than BP was observed in human 323 
skin. The permeability of the two monoesters was not changed by tape stripping 324 
in human skin, which is the same as that observed in the rat skin (Table 3). The 325 
permeation properties of other phthalate diesters through human skin were 326 
similar to those through the rat skin. BP permeated through the skin after applying 327 
DBP; however, no permeation was found after applying DEHP. 328 
 329 
Table 3 330 
 331 
Skin metabolism of phthalate diesters 332 
 333 
Metabolic experiments of phthalates were carried out in rat and human 334 
skin homogenates. DBP and BnBP were hydrolyzed to the corresponding 335 
monoesters in skin homogenates and linear Hanes-Woolf plots were obtained. 336 
Hanes-Woolf plots for hydrolysis of BnBP to BnP and BP in rat skin homogenate 337 
are shown in Figure 3. The enzymatic parameters, Km and Vmax were calculated 338 
from the slope and intercept of each plot, and the values are listed in Table 4. 339 
DEHP was not hydrolyzed to EHP, and PA was not detected in any experiment. 340 
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The Vmax value of BnBP to BP was approximately twice that of BnBP to BnP, and 341 
approximately half that of DBP to BP. However, almost same Km values were 342 
observed in the rat skin. In contrast, BnBP was metabolized more to BnP than 343 
BP, and the Km value ranged from 13 to 165 in human skin. 344 
 345 
Fig. 3 and Table 4 346 
 347 
Discussion 348 
 349 
 In the present study, we conducted a risk identification of skin 350 
permeation of various phthalates following dermal exposure. After application of 351 
DBP to the full-thickness skin of hairless rat, BP, an active metabolite, but not 352 
DBP permeated through the skin and existed inside the skin after permeation (Fig. 353 
1A and B). This shows that DBP was hydrolyzed during skin permeation, and the 354 
hydrolysis rate was greater than the skin permeation rate of DBP. Skin treatment 355 
with DFP made BP impermeable to the skin and only DBP existed in the skin (Fig. 356 
1A and B). Thus, serine esterases are responsible for DBP hydrolysis in the skin, 357 
and hydrolysis to BP is essential for skin permeation of this phthalate. Stratum 358 
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corneum-stripped skin had permeation characteristics almost the same as those 359 
in full-thickness skin (Table 2), suggesting that the main permeation barrier of 360 
DBP is not the stratum corneum but the viable epidermis and dermis. DBP may 361 
be transported easily across the stratum corneum lipids, but hardly across the 362 
water-rich viable layer owing to its high lipophilicity (ClogP = 4.73). Unlike DBP, 363 
the skin permeability of BP increased on removing the stratum corneum (Table 364 
2), indicating the stratum corneum as a main permeation barrier. DBP becomes 365 
skin permeable only after metabolizing to BP, which is relatively hydrophilic 366 
(ClogP = 2.72). DFP treatment of the skin would make DBP remain in the stratum 367 
corneum, because of its high lipophilicity. We previously reported that both ester 368 
and its monoester metabolite were transported across the skin after the 369 
application of ethyl nicotinate (Rittirod et al., 1990; Sugibayashi et al., 1996). It 370 
may be because of the lower lipophilicity of ethyl nicotinate (ClogP = 1.32) than 371 
that of DBP and BP.  372 
Skin permeability of BP was remarkably higher after applying DBP than 373 
BP directly (Table 2). When BP was applied on the skin, permeation through the 374 
stratum corneum was the rate-limiting step of the overall permeation process. 375 
This step can be overcome by substituting BP with highly lipophilic DBP. Although 376 
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the amount of DBP reaching the viable epidermis may be small, the quick 377 
conversion to BP would maintain a sink condition in the viable epidermis. In 378 
addition, the DBP in the stratum corneum would serve as a reservoir of BP. Such 379 
a reservoir effect is well known for its association with the delayed 380 
pharmacological effect of steroids (Stoughton, 1965; Abidi et al., 2012). The 381 
sustained effect of BP may cause serious results because BP is an endocrine 382 
disruptor and reproductive toxicant (Heudorf et al., 2007). We are daily exposed 383 
to phthalates by touching plastic products such as computers, 384 
smartphones, carpets, chairs and so on. Moreover, such phenomenon would 385 
depend on the metabolic activity in the skin during cutaneous absorption, as 386 
described above. 387 
 Metabolism-dependent characteristics were also observed in skin 388 
permeation of BnBP, an alkyl aryl ester of PA. In brief, the metabolites of BnBP, 389 
BnP and BP, permeated through the skin, whereas BnBP did not (Fig. 2A). The 390 
permeation of these metabolites was inhibited by DFP and only BnBP existed in 391 
DFP-treated skin (Fig. 2B). These characteristics were not changed by the 392 
removal of the stratum corneum (Table 2). Skin permeability and concentration of 393 
BP were a few times higher than that of BnP, following the application of BnBP to 394 
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the rat skin (Table 2 and Fig. 2B). The Vmax value of BP in rat skin homogenate 395 
was approximately twice as high as that of BnP, although the Km values were 396 
almost the same (Table 4). The permeability through the stripped skin was not 397 
very different between BnP and BP (Table 2). The hydrolysis rate of BnBP may 398 
reach saturation during skin permeation; thus, the difference in skin permeability 399 
and concentration between BnP and BP may be due to the difference in Vmax 400 
values.  401 
 In humans, BnP and BP were also transported across the skin after 402 
dermal application of BnBP, and the transported amounts were not changed by 403 
the removal of stratum corneum (Fig. 2C and D, Table 3). However, the apparent 404 
permeability coefficient of BP through the human skin was lower than that of BnP, 405 
in contrast to that observed in rat skin. The permeability coefficient value of BP 406 
was remarkably lower than the corresponding value in rats (Table 2). There is a 407 
species difference in skin permeation of BnBP. The human skin homogenate 408 
showed a low Vmax value of BP compared to that of BnP, and the value of BP was 409 
about one-fiftieth of that in the rat skin homogenate (Table 4). The Km values 410 
indicated that the esterases in human skin have a lower affinity to BP than BnP, 411 
and the affinity of rat esterases to the two phthalates were almost the same. It 412 
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was reported that species differences exist in the metabolic capacity of DEHP (Ito 413 
et al., 2005), and these differences cause pharmacokinetic differences among 414 
species (Adachi et al., 2015). However, metabolic data in the skin is not available 415 
despite different enzyme expression among the tissues (Imai, 2006). We 416 
confirmed that no DEHP is hydrolyzed to EHP in skin homogenates and 417 
transported across the skin. Species difference is also observed in the skin 418 
permeability of chemicals not being dermally metabolized, but it can easily be 419 
predicted from the physicochemical properties of chemicals. Many in silico 420 
estimation methods have been proposed for dermally unmetabolized chemicals 421 
(Potts and Guy, 1992; Vecchia and Bunge 2002; Hatanaka et al., 2014; Chen et 422 
al., 2015). Nevertheless, skin permeation characteristics of dermally metabolized 423 
chemicals differ quantitatively and qualitatively among species. Therefore, the 424 
characteristics of human skin cannot be estimated from those of animal skin. 425 
Moreover, inter-individual difference in metabolic activity is often larger than the 426 
species difference (Ito et al., 2014). An accurate estimation of esterase activity 427 
in the skin is necessary.  428 
 We used the frozen skin to get the human data, because the fresh 429 
human skin is rather hard to obtain. The influence of freezing was evaluated 430 
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on the skin permeation and metabolism by many researchers, and the 431 
extent of influence was remarkably different depending on the permeants, 432 
animal species and storage procedures (Hewitt et al., 2000; Lau et al., 2012; 433 
Pažoureková et al., 2013; Sintov, 2017). In the present study, the 434 
permeability of phthalates through the human skin may be overestimated 435 
and the metabolic activity in the skin may be underestimated. Even if those 436 
are so, the metabolism-dependent percutaneous absorption of phthalates 437 
occurs, as long as phthalates without biotransformation to monoester 438 
metabolites cannot be transported across the water-rich viable layers of 439 
skin. The obtained permeation and metabolic profiles may not be general 440 
in human skin, because only four pieces of skin from two female subjects 441 
could be used in the present study. We have already obtained a transgenic 442 
mouse to which a certain human esterase gene is transferred. The skin 443 
homogenate of transgenic mouse showed a low Vmax value of BP compared 444 
to that of BnP, in contrast to that observed in skin homogenate of wild type 445 
mouse (data not shown). These results support the species differences 446 
observed in the present study. Further study will be required to clarify the 447 
species differences in skin permeation characteristics of dermal 448 
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metabolized chemicals such as phthalates. 449 
 450 
Conclusion 451 
 452 
 Phthalates were absorbed percutaneously as well as through oral and 453 
transpulmonary routes. Considering the large surface area of the skin and 454 
repeated contact with plastics, the percutaneous absorption of phthalates cannot 455 
be ignored. Dialkyl phthalates were hydrolyzed to monoester metabolites during 456 
skin permeation. Skin metabolism is a key event for the percutaneous absorption 457 
of phthalates and their metabolites. Highly lipophilic phthalates may be easily 458 
transported across the stratum corneum lipids, and the water-rich viable layers 459 
become more permeable to phthalates by metabolizing to monoesters, which are 460 
relatively hydrophilic. The permeated amount of phthalates depends on the 461 
esterase activity in the skin, which is remarkably different among species and 462 
individuals. Further study will be needed for individual risk identification of 463 
dermal exposure to phthalates. 464 
 465 
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Figure Legends 575 
 576 
Fig. 1. Skin permeation profiles and skin concentrations of phthalates after 577 
applying DBP to excised hairless rat skin. (A), cumulative amount of DBP and its 578 
monoester metabolite, BP, that permeated through full-thickness skin; (B), 579 
phthalate concentrations after permeation experiment in full-thickness skin 580 
untreated or treated with DFP; (C), cumulative amount of DBP and BP that 581 
permeated through stripped skin; (D), phthalate concentration after permeation 582 
experiment in stripped skin untreated or treated with DFP. N.D. means “not 583 
detected.” Each point represents the mean ± S.D. (n = 4). 584 
Fig. 2. Skin permeation profiles and skin concentrations of phthalates after 585 
applying BnBP to excised hairless rat and human skins. (A), cumulative amount 586 
of BnBP and its monoester metabolites, BP and BnP, that permeated through full-587 
thickness rat skin; (B), phthalate concentration after permeation experiment in 588 
full-thickness rat skin untreated or treated with DFP; (C), cumulative amount of 589 
BnBP, BP, and BnP that permeated through full-thickness human skin; (D), 590 
phthalate concentration after permeation experiment in full-thickness human skin. 591 
N.D. means “not detected.” Each point represents the mean ± S.D. (n = 4). 592 
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Fig. 3. Hanes-Woolf plot for hydrolysis of BnBP to BnP and BP in rat skin 593 
homogenate. 594 
  595 
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Table 1   596 
Physicochemical properties of phthalates used as permeants in this study. 597 
CAS No. 
Compounds name 
(abbreviation) 
Structural fomula 
Chemical formula 
(Molecular weight) 
ClogPa 
84-74-2 
Dibutyl phthalate 
(DBP) 
 
C16H22O4 
(278.3) 
4.73 
85-68-7 
Benzyl butyl 
phthalate 
(BnBP) 
 
C19H20O4 
(312.4) 
4.97 
117-81-7 
Di (2-ethylhexyl) 
phthalate 
(DEHP) 
 
C24H38O4 
(390.6) 
8.71 
131-70-4 
Monobutyl 
phthalate 
(BP) 
 
C12H14O4 
(222.2) 
2.72 
2528-16-7 
Monobenzyl 
phthalate 
(BnP) 
 
C14H10O4 
(256.25) 
3.23 
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4376-20-9 
Mono (2-ethylhexyl) 
phthalate 
(EHP) 
 
C16H22O4 
(278.3) 
4.71 
a Logarithm of n-octanol/water partition coefficient calculated by Chem Draw Ultra 12.2® 598 
(PerkinElmer informatics, Cambridge, MA). 599 
  600 
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Table 2 601 
Permeability coefficients of phthalates through hairless rat skina. 602 
a Mean ± S.D. of 3–5 experiments. When the permeated chemical differed from 603 
the applied chemical, the values were the apparent permeability coefficients. 604 
Refer to Data analysis for details. 605 
b Permeability coefficient through the full-thickness skin. 606 
c Permeability coefficient through the stripped skin. 607 
d Not detected. 608 
Applied  
chemical 
Permeated  
chemical 
Pfull-thicknessb 
(cm/s) 
Pstrippedc 
(cm/s) 
DBP BP 7.3×10-5 ± 1.4×10-5 6.8×10-5 ± 2.2×10-5 
BnBP 
BnP 9.2×10-7 ± 6.1×10-8 9.0×10-7 ± 1.5×10-7 
BP 6.0×10-6 ± 2.2×10-6 3.5×10-6 ± 1.1×10-6 
BP BP 2.4×10-7 ± 1.4×10-7 4.2×10-6 ± 2.1×10-6 
BnP BnP 3.6×10-8 ± 8.7×10-9 4.4×10-6 ± 8.2×10-7 
EHP EHP N.D.d 4.5×10-8 ± 6.9×10-9 
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Table 3 609 
Permeability coefficients of phthalates through human skina. 610 
Applied 
chemical 
Permeated 
chemical 
Pfull-thicknessb  
(cm/s) 
Pstrippedc 
(cm/s) 
DBP BP 8.6×10-6 ± 4.7×10-7 7.2×10-6 ± 1.1×10-6 
BnBP 
BnP 1.1×10-6 ± 2.4×10-7 1.5×10-6 ± 6.0×10-7 
BP 2.7×10-7 ± 4.3×10-7 2.5×10-7 ± 1.5×10-7 
a Mean of 3–5 experiments. When the permeated chemical differed from the 611 
applied chemical, the values were the apparent permeability coefficients. Refer 612 
to Data analysis for details. 613 
b Permeability coefficient through the full-thickness skin. 614 
c Permeability coefficient through the stripped skin. 615 
  616 
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Table 4 617 
Metabolic parameters for hydrolysis of DBP and BnBP in rat and human skin 618 
homogenates.  619 
Species Substrate Product Km (μM) 
Vmax (nmol/min/ 
mg protein) 
Rat DBP BP 18 2.9×10-1 
 BnBP BnP 19 5.2×10-2 
  BP 15 1.3×10-1 
Human DBP BP 13 4.1×10-2 
 BnBP BnP 59 4.7×10-2 
  BP 165 2.6×10-3 
  620 
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Fig. 2 624 
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Fig. 3 628 
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